

Appl. No. 10/541,086  
Amdt. Dated April 24, 2008  
Reply to Office Action of January 24, 2008

Attorney Docket No. 89188.0115  
Customer No.: 26021

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-24. (canceled)

25. (Currently Amended): An isolated mammalian polypeptide comprising the sequence of SEQ ID NO: 1, ~~SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, or SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27 or SEQ ID NO: 29, or variant polypeptides corresponding to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27 or SEQ ID NO: 29, in which one or more amino acids are replaced, deleted, inserted and/or added.~~

26. (Withdrawn): An isolated mammalian polypeptide comprising the sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28 or SEQ ID NO: 30, or variant polypeptides corresponding to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10 or SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28 or SEQ ID NO: 30, in which one or more amino acids are replaced, deleted, inserted and/or added.

27. (Currently Amended): An isolated mammalian polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 5, ~~SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15 or SEQ ID NO: 19, or variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 1 SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID~~

Appl. No. 10/541,086  
Amdt. Dated April 24, 2008  
Reply to Office Action of January 24, 2008

Attorney Docket No. 89188.0115  
Customer No.: 26021

~~NO: 13 or SEQ ID NO: 17, in which one or more amino acids are replaced, deleted, inserted and/or added.~~

28. (Withdrawn): An isolated mammalian polypeptide encoded by the nucleic acid sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16 or SEQ ID NO: 20, or variant nucleic acids that encode for variant polypeptides corresponding to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 14 or SEQ ID NO: 18, in which one or more amino acids are replaced, deleted, inserted and/or added.

29. (Currently Amended): A composition comprising the The polypeptide of claim 25 contained in a suitable pharmaceutical composition and a pharmaceutically acceptable carrier suitable for delivery to a subject.

30. (Previously presented): The polypeptide of claim 29, wherein in the subject is human.

31. (Withdrawn): The polypeptide of claim 26 contained in a suitable pharmaceutical composition for delivery to a subject.

32. (Canceled)

33. (Previously presented): The polypeptide of claim 25, comprising one or more antigenic polypeptide sequences.

34. (Previously presented): The polypeptide of claim 33, wherein the one or more antigenic polypeptide sequences specifically binds to one or more isolated antibodies.

35. (Withdrawn): The polypeptide of claim 26, comprising one or more antigenic polypeptide sequences.

36. (Withdrawn): The polypeptide of claim 35, wherein the one or more antigenic polypeptide sequences specifically binds to one or more isolated antibodies.

37. (Currently Amended): The polypeptide of claim 25, wherein the polypeptide binds to a binding partner located on a cell membrane with a Kd-Kd of approximately ~~10<sup>-8</sup>M-10<sup>-8</sup>M~~ or greater.

38. (Previously presented): The polypeptide of claim 37, wherein when the polypeptide binds to the binding partner located on the cell membrane, the binding produces a molecular signal that is transmitted to the interior of the cell.

39. (Withdrawn): The polypeptide of claim 26, wherein the polypeptide binds to a binding partner located on a cell membrane with a Kd of approximately 10<sup>-8</sup>M or greater.

40. (Withdrawn): The polypeptide of claim 39, wherein when the polypeptide binds to the binding partner located on the cell membrane, the binding interaction produces a molecular signal that is transmitted to the interior of the cell.

Appl. No. 10/541,086  
Amdt. Dated April 24, 2008  
Reply to Office Action of January 24, 2008

Attorney Docket No. 89188.0115  
Customer No.: 26021

41.(Currently Amended): The An isolated polypeptide produced by a method comprising:

providing a suitable nucleic acid vector for delivery into a cell ~~of claim 27,~~  
wherein the nucleic acid sequence of the vector corresponding to the peptide of claim 27 is contained in a ~~the~~ suitable nucleic acid vector for delivery into a cell;,  
delivering said vector to said cell and wherein the vector contained in the cell permits expression of the polypeptide within the cell; and  
isolating the polypeptide from the cell.

42. (Currently Amended): The polypeptide of claim 41, wherein the expressed polypeptide is subsequently secreted from the cell prior to being isolated.

43. (Withdrawn): The polypeptide of claim 28, wherein the nucleic acid sequence corresponding to the peptide is contained in a suitable nucleic acid vector for delivery into a cell, and wherein the vector contained in the cell permits expression of the polypeptide within the cell.

44. (Withdrawn): The polypeptide of claim 43, wherein the expressed polypeptide is subsequently bound to the cell membrane.